cutaneous T-cell lymphoma
Haematology · 2011–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mogamulizumab Treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) previously treated with at least one… | Sep 2025 | Recommended with restriction | 15 individuals Leukaemia Foundation · Rare Cancers Australia |
| mogamulizumab Relapsed or refractory cutaneous T cell lymphoma (CTCL) following at least one prior systemic treatment, with clinical evidence specifically in mycosis… | Jul 2020 | Not recommended | 1 individuals Leukaemia Foundation · Rare Cancers Australia |
| methoxsalen Treatment of patients with erythrodermic stage III-IVa T4M0 cutaneous T-cell lymphoma (CTCL) who are refractory to one or more systemic treatments, delivered… | May 2020 | Recommended with restriction | no section in document |
| mogamulizumab Treatment of patients with relapsed or refractory cutaneous T cell lymphoma (CTCL) with mycosis fungoides (MF) or Sézary syndrome (SS) following at least one… | Nov 2020 | Not recommended | input received Leukaemia Foundation |
| brentuximab vedotin Treatment of relapsed or refractory CD30 positive cutaneous T-cell lymphoma (CTCL) in patients who have previously used systemic therapy. | Jul 2018 | Not recommended | 8 individuals |
| brentuximab vedotin Treatment of refractory or relapsed CD30 positive cutaneous T-cell lymphomas (CTCL), including mycosis fungoides, Sézary syndrome, and primary cutaneous… | Nov 2018 | Recommended with restriction | none received |
| methoxsalen Treatment of cutaneous T-cell lymphoma (CTCL), specifically erythrodermic stage III-IVa (T4, M0) CTCL in patients refractory to methotrexate or one or more… | Jul 2017 | Deferred | none received |
| vorinostat Cutaneous T-cell lymphoma (CTCL) in patients with relapsed or chemotherapy-refractory disease who are ineligible for stem cell transplantation. | Mar 2017 | Recommended with restriction | none received |
| vorinostat Treatment of relapsed or chemotherapy-refractory cutaneous T-cell lymphoma (CTCL) in patients who have received and failed prior systemic therapy, are not… | Nov 2016 | Deferred | 2 individuals Rare Cancers Australia |
| vorinostat Treatment of advanced (stage IIB-IV) cutaneous T-cell lymphoma (CTCL) where treatment has failed with four systemic therapies. | Mar 2011 | Not recommended | unclear |
Who spoke
Leukaemia Foundation · Rare Cancers Australia
What the PBS pays
$23M in government benefit over 2024–25, across 2,911 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| brentuximab vedotin | $21.4M |
| vorinostat | $0.9M |
| methoxsalen | $0.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 9 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.